DEA proposes Schedule I classification for five synthetic tryptamine psychedelics, threatening research and clinical development

The U.S. Drug Enforcement Administration has proposed placing five synthetic tryptamines - 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT - in Schedule I under the Controlled Substances Act. If finalized, the rule would make non-research possession, manufacture, and distribution federal felonies while requiring researchers to navigate costly DEA registration, security, reporting, Institutional Review Board, and potentially FDA requirements. The proposal cites pharmacological evidence, adverse-effect reports, abuse concerns, and the absence of accepted medical use, but the compounds have limited prevalence data, sparse toxicity research, and no large clinical trials or FDA New Drug Applications. The briefing warns that scheduling could chill basic research, hinder analytical standards, push markets toward unscheduled analogs, complicate harm reduction, and establish a precedent for rapid action against emerging psychoactive substances. Public comments offer stakeholders a limited opportunity to influence the final rule.